Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C38H50N6O9S |
Molecular Weight | 766.903 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]1([H])OC(=O)N[C@H](C(=O)N3C[C@@]([H])(C[C@H]3C(=O)N[C@@]4(C[C@@]4([H])C=C)C(=O)NS(=O)(=O)C5CC5)OC6=NC7=CC(OC)=CC=C7N=C6CCCCC2)C(C)(C)C
InChI
InChIKey=OBMNJSNZOWALQB-NCQNOWPTSA-N
InChI=1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1
Molecular Formula | C38H50N6O9S |
Molecular Weight | 766.903 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Grazoprevir is a second generation NS3/4A protease inhibitor approved in the EU and the USA for the treatment of hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients in combination with elbasvir (C virus (HCV) NS5A inhibitor) as the fixed-dose combination product Zepatier with or without ribavirin. In phase III trials, 12 or 16 weeks of treatment with once-daily elbasvir/grazoprevir (fixed-dose tablet or as individual agents), taken with or without ribavirin, generally provided high rates of sustained virological response at 12 weeks (SVR12) in treatment-naive and -experienced adult patients with chronic HCV genotype 1a, 1b or 4 infection, including those with or without compensated cirrhosis, HIV co-infection, inherited blood disorders or chronic kidney disease or patients receiving opioid agonist therapy or of Japanese origin. Elbasvir/grazoprevir was generally well tolerated. Thus, elbasvir/grazoprevir, with or without ribavirin, represents an effective new option for the treatment of adults with chronic HCV genotype 1 and 4 infection, including a number of difficult-to-treat populations.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.02 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZEPATIER Approved UseZEPATIER is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated for treatment of chronic HCV genotype 1 or 4 infection in adults. ZEPATIER is indicated for use with ribavirin in certain patient populations. Launch Date2016 |
Sample Use Guides
ZEPATIER is a two-drug, fixed-dose combination product containing 50 mg of elbasvir and 100 mg of grazoprevir in a single tablet. The recommended dosage of ZEPATIER is one tablet taken orally once daily with or without food
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22615282
In a cell-based replicon system, MK-5172 (Grazoprevir) inhibited HCV with EC50 values of 2 nM against genotype 1a, 0.5 nM against genotype 1b, 8 nM against genotype 2a and 13 nM against genotype 3. Also, MK-5172 is effective against HCV genotypes 1a, 2a, 1b, 2b and 3a.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:40:38 GMT 2023
by
admin
on
Sat Dec 16 08:40:38 GMT 2023
|
Record UNII |
8YE81R1X1J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000182639
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000160903
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
1350514-68-9
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
N0000190114
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | Cytochrome P450 3A Inhibitors [MoA] | ||
|
9857
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
m11947
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
8YE81R1X1J
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
SUB174126
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
1206524-75-5
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
SUPERSEDED | |||
|
C175724
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
1871173
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
1356446-42-8
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
SUPERSEDED | |||
|
DTXSID50159234
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
N0000182638
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | HCV NS3/4A Protease Inhibitors [MoA] | ||
|
44603531
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
8YE81R1X1J
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | |||
|
N0000190113
Created by
admin on Sat Dec 16 08:40:38 GMT 2023 , Edited by admin on Sat Dec 16 08:40:38 GMT 2023
|
PRIMARY | Breast Cancer Resistance Protein Inhibitors [MoA] |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
SOLVATE->ANHYDROUS | |||
|
TRANSPORTER -> SUBSTRATE |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||